Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180046/S102

Axonics Sacral Neuromodulation System

BOSTON SCIENTIFIC CORPORATION · Decision date Jan 7, 2026

FDA DECISIONP180046/S102

What did the FDA decide?

FDA records P180046/S102 as a supplement to PMA P180046, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 7, 2026.

FDA approval order statement

to perform Bacterial Endotoxin Testing (BET) pre-sterilization
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Jan 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P180046/S102
Regulatory pathway
PMA supplement
Product code
EZW
Decision code
OK30
Decision date
Jan 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implantable, for incontinence.

Product code
EZW
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180046/S102 received

    Application receipt date recorded by FDA.

  2. P180046/S101 · Related supplement

    Axonics Sacral Neuromodulation System

  3. P180046/S102 · FDA decision

    30-Day Notice

  4. P180046/S103 · Related supplement

    Axonics Sacral Neuromodulation System

  5. P180046/S104 · Related supplement

    Axonics Sacral Neuromodulation System

  6. P180046/S106 · Related supplement

    Axonics Sacral Neuromodulation System

  7. P180046/S108 · Related supplement

    Axonics Sacral Neuromodulation System

  8. P180046/S105 · Related supplement

    Axonics Sacral Neuromodulation System

  9. P180046/S107 · Related supplement

    Axonics Sacral Neuromodulation System

  10. P180046/S099 · Related supplement

    Axonics Sacral Neuromodulation System

  11. P180046/S100 · Related supplement

    Axonics Sacral Neuromodulation System

  12. P180046/S109 · Related supplement

    Axonics Sacral Neuromodulation System

  13. P180046/S111 · Related supplement

    Axonics Sacral Neuromodulation System

  14. P180046/S110 · Related supplement

    Axonics Sacral Neuromodulation System

  15. P180046/S113 · Related supplement

    Axonics Sacral Neuromodulation System

Timeline entries are records held by MedtechLedger for P180046. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180046

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementDec 19, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJan 13, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJan 14, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 24, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 25, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 27, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 27, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMar 9, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMar 27, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementApr 7, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMay 29, 2026FDA
Axonics SNM SystemP180046/S112
BOSTON SCIENTIFIC CORPORATIONPMA supplementJun 17, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 24, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 7, 2026FDA

Explore the linked device profile

Other records with product code EZW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
100 Boston Scientfic Way, Marlborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records